Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
NCT ID: NCT01187303
Last Updated: 2015-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
28 participants
INTERVENTIONAL
2011-05-31
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT01060384
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT01190449
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
NCT00478959
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT00540007
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
NCT01078922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ofatumumab
300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 18 - 75
* review of diagnosis by experienced pathologist
* no major organ dysfunction
Exclusion Criteria
* CD20 antibody treatment within the last 6 months prior enrollment
* chronic or current infectious disease requirering systemic antibiotics
* other past or current malignancy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cologne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Andreas Engert
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Engert, MD
Role: PRINCIPAL_INVESTIGATOR
University of Cologne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1st Department of Medicine, Cologne University Hospital
Cologne, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Homepage of the German Hodgkin Study Group
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Uni-Koeln-1432
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.